Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sustol
- Development stage
- Unknown
- Lead developer
- Heron Therapeutics
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Subcutaneous
01
Overview
Sustol (APF530) is an extended-release formulation of the 5-HT3 receptor antagonist granisetron, developed by Heron Therapeutics. It utilizes a proprietary Biochronomer polymer-based drug delivery technology, which consists of a bioerodible tri(ethylene glycol) poly(orthoester) polymer. This technology allows for the sustained release of granisetron, maintaining therapeutic drug levels for at least five days following a single subcutaneous injection. Sustol is specifically indicated for use in combination with other antiemetics in adults for the prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) associated with initial and repeat courses of moderately emetogenic chemotherapy (MEC) or anthracycline and cyclophosphamide (AC) combination chemotherapy regimens. By providing extended coverage, it addresses the clinical challenge of delayed-onset emesis, which is often poorly controlled by conventional, short-acting 5-HT3 receptor antagonists.
- Brand names
- Sustol
- Other names
- granisetron extended-release injection
02
Targets
HTR3A (5-hydroxytryptamine receptor 3A)
Beyond the preview
Go deeper on Sustol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sustol.